Lower Respiratory Tract Therapeutics Global Market Report 2024

The lower respiratory tract therapeutics market size has grown strongly in recent years. It will grow from $32.91 billion in 2023 to $35.8 billion in 2024 at a compound annual growth rate (CAGR) of 8.8%. The growth observed in the historical period in lower respiratory tract therapeutics can be attributed to several factors. These include significant discoveries in antibiotics, the implementation of vaccination programs, campaigns promoting smoking cessation, advancements in inhalation therapy, and the overall growth of healthcare infrastructure. These factors collectively contributed to improved prevention, diagnosis, and treatment of lower respiratory tract disorders during the specified historical timeframe.

The lower respiratory tract therapeutics market size is expected to see strong growth in the next few years. It will grow to $48.37 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The anticipated growth in the forecast period for lower respiratory tract therapeutics can be attributed to several factors. These include the escalation of air pollution levels, an aging population leading to increased respiratory issues, the challenge of antimicrobial resistance, and the impact of various environmental factors. Key trends expected during this period encompass the adoption of precision medicine approaches, ongoing technological innovations in the field, the emergence of biologic therapies, the integration of telehealth in respiratory care, and the development of personalized inhalation devices. These trends collectively reflect the evolving landscape of lower respiratory tract therapeutics, driven by advancements in healthcare and a focus on personalized and innovative treatment approaches.

The escalating occurrence of respiratory ailments is poised to significantly bolster the lower respiratory tract therapeutics market in the forthcoming period. Respiratory illnesses encompass a range of medical conditions impacting the respiratory system, including the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. Lower respiratory tract therapeutics play a pivotal role in the early identification and diagnosis of these conditions, enabling timely intervention and management. This proactive approach aids in halting disease progression, controlling the spread of infectious respiratory diseases, and mitigating the likelihood of complications. As per data reported in September 2022 by the NCD Alliance, a civil society organization based in Switzerland, lung cancer stood as the leading cause of global cancer-related deaths, foreseeing an annual estimate of 2.2 million new cases and 1.8 million fatalities. Furthermore, chronic respiratory disorders impacted 550 million adults worldwide, resulting in 4.2 million deaths, constituting 7% of all mortalities. Thus, the escalating prevalence of respiratory diseases is set to act as a major impetus driving the growth of the lower respiratory tract therapeutics market.

The increasing prevalence of smoking is anticipated to be a key driving force behind the growth trajectory of the lower respiratory tract therapeutics market. Smoking denotes the inhalation and exhalation of smoke derived from burning tobacco or other substances. Lower respiratory tract therapeutics are instrumental in mitigating inflammation, alleviating symptoms, slowing down disease progression, enhancing airflow and lung function, reducing exacerbation frequency and severity, improving oxygenation, and augmenting the prospects of successful smoking cessation. For instance, a report from The World Health Organization, an intergovernmental organization headquartered in Switzerland, revealed that over 8 million individuals succumb to tobacco-related causes annually, including 1.3 million non-smokers exposed to second-hand smoke. Consequently, the mounting prevalence of smoking is emerging as a significant factor fueling the expansion of the lower respiratory tract therapeutics market.

Advancements in product innovations stand out as a prominent trend within the lower respiratory tract therapeutics market. Major players in this domain are actively introducing novel products to fortify their positions in the market. For instance, in 2022, AstraZeneca plc, a pharmaceutical and biotechnology company based in the UK, collaborated with Sanofi S.A., a French pharmaceutical company, to introduce Beyfortus. This medication received approval from the European Union (E.U.) as a preventive measure against respiratory syncytial virus (RSV) and lower respiratory tract illnesses in newborns and infants during their initial RSV season. Markedly, Beyfortus represents the first single-dose RSV passive vaccination targeting the general newborn population, encompassing healthy infants, full-term or preterm babies, and those with specific medical conditions.

Major players operating in the lower respiratory tract therapeutics market are concentrating on innovative offerings such as triple combination drugs tailored for COPD management to bolster their market revenues. This triple combination therapy for COPD comprises long-acting muscarinic antagonists (LAMA), long-acting beta-agonists (LABA), and inhaled corticosteroids (ICS) as the three primary inhaled medications. For instance, Lupin Limited, a pharmaceutical company based in India, introduced Vilfuro-G in November 2023. Vilfuro-G, available in a fixed dosage strength with once-daily dosing recommendations, is poised to significantly enhance the lives of COPD patients. This launch demonstrates Lupin's commitment to expanding its respiratory product line and providing healthcare professionals and patients with state-of-the-art treatment alternatives. Notably, Vilfuro-G stands as the only fixed-dose combination specifically formulated to combine glycopyrronium bromide, vilanterol, and fluticasone furoate for the long-term treatment and management of moderate to severe COPD.

In June 2022, Pfizer Inc., a prominent US-based pharmaceutical and biotechnology company, successfully acquired ReViral for an undisclosed amount. Through this acquisition, Pfizer seeks to broaden its portfolio of potential treatment options, with a particular focus on sisunatovir. Sisunatovir is an orally administered inhibitor specifically designed to prevent the respiratory syncytial virus (RSV) from attaching to the host cell's membrane. ReViral Ltd., the UK-based biopharmaceutical company that Pfizer acquired, is known for its dedication to developing novel antiviral therapeutics with a focus on targeting respiratory syncytial virus.

Major companies operating in the lower respiratory tract therapeutics market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., Menarini Group, Chiesi Farmaceutici S.p.A., Cipla Limited, BioMarin Pharmaceutical Inc., Mundipharma International Limited, Orion Corporation, Sunovion Pharmaceuticals Inc., Innoviva Inc., Insmed Incorporated, Vectura Group plc, Kamada Ltd., Theravance Biopharma Inc., Verona Pharma plc, Circassia Pharmaceuticals plc.

North America was the largest region in the lower respiratory tract therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lower respiratory tract therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lower respiratory tract therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary disease types addressed by lower respiratory tract therapeutics include asthma, chronic obstructive pulmonary disease (COPD), pneumonia, tuberculosis, bronchitis, and others. Asthma, for instance, is a chronic respiratory disorder characterized by inflammation of the airways, resulting in their narrowing and leading to frequent bouts of coughing, wheezing, chest tightness, and shortness of breath. Various drug classes are employed in lower respiratory tract therapeutics, including antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), cough suppressants, nasal decongestants, and others. These therapeutics are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, providing individuals with access to the necessary medications for managing lower respiratory tract conditions.

The lower respiratory tract therapeutics market research report is one of a series of new reports that provides lower respiratory tract therapeutics market statistics, including lower respiratory tract therapeutics industry global market size, regional shares, competitors with lower respiratory tract therapeutics market share, detailed lower respiratory tract therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the lower respiratory tract therapeutics industry. This lower respiratory tract therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lower respiratory tract therapeutics market consists of sales of beta-lactam antibiotics, macrolides, and fluoroquinolones. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.


The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.